Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer

被引：65

作者：

Root, Adam R. ^{[1
]}

Cao, Wei ^{[1
]}

Li, Bilian ^{[1
]}

LaPan, Peter ^{[1
]}

Meade, Caryl ^{[1
]}

Sanford, Jocelyn ^{[1
]}

Jin, Macy ^{[1
]}

O'Sullivan, Cliona ^{[2
]}

Cummins, Emma ^{[2
]}

Lambert, Matthew ^{[2
]}

Sheehan, Alfredo D. ^{[2
]}

Ma, Weijun ^{[1
]}

Gatto, Scott ^{[1
]}

Kerns, Kelvin ^{[1
]}

Lam, Khetemenee ^{[1
]}

D'Antona, Aaron M. ^{[1
]}

Zhu, Lily ^{[1
]}

Brady, William A. ^{[1
]}

Benard, Susan ^{[1
]}

King, Amy ^{[1
]}

He, Tao ^{[1
]}

Racie, Lisa ^{[1
]}

Arai, Maya ^{[1
]}

Barrett, Dianah ^{[1
]}

Stochaj, Wayne ^{[1
]}

LaVallie, Edward R. ^{[1
]}

Apgar, James R. ^{[1
]}

Svenson, Kristine ^{[1
]}

Mosyak, Lidia ^{[1
]}

Yang, Yinhua ^{[3
]}

Chichili, Gurunadh R. ^{[3
]}

Liu, Liqin ^{[3
]}

Li, Hua ^{[3
]}

Burke, Steve ^{[3
]}

Johnson, Syd ^{[3
]}

Alderson, Ralph ^{[3
]}

Finlay, William J. J. ^{[2
]}

Lin, Laura ^{[1
]}

Olland, Stephane ^{[1
]}

Somers, William ^{[1
]}

Bonvini, Ezio ^{[3
]}

Gerber, Hans-Peter ^{[4
]}

May, Chad ^{[4
]}

Moore, Paul A. ^{[3
]}

Tchistiakova, Lioudmila ^{[1
]}

Bloom, Laird ^{[1
]}

机构：

[1] Pfizer Inc, Global Biotherapeut Technol, 610 Main St, Cambridge, MA 02139 USA

[2] Pfizer Inc, Global Biotherapeut Technol, Grange Castle Business Pk, Dublin 22, Ireland

[3] MacroGenics Inc, 9640 Med Ctr Dr, Rockville, MD 20850 USA

[4] Pfizer Inc, Oncol Res Unit, 401 N Middletown Rd, Pearl River, NY 10965 USA

来源：

ANTIBODIES | 2016年 / 5卷 / 01期

关键词：

P-cadherin; bispecific; cancer; immuno-oncology; T-cell; re-targeting;

D O I：

10.3390/antib5010006

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Bispecific antibodies offer a promising approach for the treatment of cancer but can be challenging to engineer and manufacture. Here we report the development of PF-06671008, an extended-half-life dual-affinity re-targeting (DART((R))) bispecific molecule against P-cadherin and CD3 that demonstrates antibody-like properties. Using phage display, we identified anti-P-cadherin single chain Fv (scFv) that were subsequently affinity-optimized to picomolar affinity using stringent phage selection strategies, resulting in low picomolar potency in cytotoxic T lymphocyte (CTL) killing assays in the DART format. The crystal structure of this disulfide-constrained diabody shows that it forms a novel compact structure with the two antigen binding sites separated from each other by approximately 30 angstrom and facing approximately 90 degrees apart. We show here that introduction of the human Fc domain in PF-06671008 has produced a molecule with an extended half-life (similar to 4.4 days in human FcRn knock-in mice), high stability (T(m)1 > 68 degrees C), high expression (>1 g/L), and robust purification properties (highly pure heterodimer), all with minimal impact on potency. Finally, we demonstrate in vivo anti-tumor efficacy in a human colorectal/human peripheral blood mononuclear cell (PBMC) co-mix xenograft mouse model. These results suggest PF-06671008 is a promising new bispecific for the treatment of patients with solid tumors expressing P-cadherin.

引用

页数：30

共 4 条

[1] A 5T4 x CD3 bispecific DART® molecule with extended half-life for T-cell immunotherapy of cancers
Huang, Ling
Chichili, Gurunadh
Alderson, Ralph
Chen, Francine
Brown, Jennifer
Li, Hua
Ciccarone, Valentina
Tamura, Jim
Liu, Daorong
Liu, Liqin
Johnson, Syd
Bonvini, Ezio
Moore, Paul
CANCER RESEARCH, 2017, 77
[2] AI-guided generation and development of HXN-1001, a highly potent and half-life extended anti-TL1A antibody
Huang, J.
Ran, H.
Li, S.
Su, C.
Chen, C.
Liu, D.
Pan, Y.
Xu, X.
Chen, X.
Fei, K.
Tian, J.
Wang, M.
Tian, L.
Peng, J.
Zhu, Z.
JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1597 - i1597
[3] Combination of AMG 160, a PSMA x CD3 half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, with an anti-PD-1 antibody in prostate cancer (PCa)
Paweletz, Katherine L.
Li, Shyun
Bailis, Julie M.
Juan, Gloria
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[4] Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Subklewe, Marion y
Stein, Anthony
Walter, Roland B.
Bhatia, Ravi
Wei, Andrew H.
Ritchie, David
Bucklein, Veit
Vachhani, Pankit
Dai, Tian
Hindoyan, Antreas
Agarwal, Suresh
Anderson, Abraham
Khaldoyanidi, Sophia
Ravandi, Farhad
BLOOD, 2019, 134

← 1 →